Vaccinia viruses with mutations in the E3L gene as potential replication-competent, attenuated vaccines: Scarification vaccination

Garilyn M. Jentarra, Michael C. Heck, Jin Won Youn, Karen Kibler, Jeffrey Langland, Carole R. Baskin, Olga Ananieva, Yung Chang, Bertram Jacobs

Research output: Contribution to journalArticle

31 Scopus citations


In this study, we evaluated the efficacy of vaccinia virus (VACV) containing mutations in the E3L virulence gene to protect mice against a lethal poxvirus challenge after vaccination by scarification. VACV strains with mutations in the E3L gene had significantly decreased pathogenicity, even in immune deficient mice, yet retained the ability to produce a potent Th1-dominated immune response in mice after vaccination by scarification, while protecting against challenge with wild type, pathogenic VACV. Initial experiments were done using the mouse-adapted, neurovirulent Western Reserve (WR) strain of vaccinia virus. Testing of the full E3L deletion mutation in the Copenhagen and NYCBH strains of VACV, which are more appropriate for use in humans, produced similar results. These results suggest that highly attenuated strains of VACV containing mutations in E3L have the potential for use as scarification administered vaccines.

Original languageEnglish (US)
Pages (from-to)2860-2872
Number of pages13
Issue number23
StatePublished - Jun 2 2008



  • E3L
  • Smallpox vaccine
  • Vaccinia

ASJC Scopus subject areas

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • veterinary(all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Cite this